Literature DB >> 31669433

Rate and Predictors of Bacteremia in Afebrile Community-Acquired Pneumonia.

Christina Forstner1, Vladimir Patchev2, Gernot Rohde3, Jan Rupp4, Martin Witzenrath5, Tobias Welte6, Heinz Burgmann7, Mathias W Pletz8.   

Abstract

BACKGROUND: Although blood cultures (BCs) are the "gold standard" for detecting bacteremia, the utility of BCs in patients with community-acquired pneumonia (CAP) is controversial. This study describes the proportion of patients with CAP and afebrile bacteremia and identifies the clinical characteristics predicting the necessity for BCs in patients who are afebrile.
METHODS: Bacteremia rates were determined in 4,349 patients with CAP enrolled in the multinational cohort study The Competence Network of Community-Acquired Pneumonia (CAPNETZ) and stratified by presence of fever at first patient contact. Independent predictors of bacteremia in patients who were afebrile were determined using logistic regression analysis.
RESULTS: Bacteremic pneumonia was present in 190 of 2,116 patients who were febrile (8.9%), 101 of 2,149 patients who were afebrile (4.7%), and one of 23 patients with hypothermia (4.3%). Bacteremia rates increased with the CURB-65 score from 3.5% in patients with CURB-65 score of 0 to 17.1% in patients with CURB-65 score of 4. Patients with afebrile bacteremia exhibited the highest 28-day mortality rate (9.9%). Positive pneumococcal urinary antigen test (adjusted OR [AOR], 4.6; 95% CI, 2.6-8.2), C-reactive protein level > 200 mg/L (AOR, 3.1; 95% CI, 1.9-5.2), and BUN level ≥ 30 mg/dL (AOR, 3.1; 95% CI, 1.9-5.3) were independent positive predictors, and antibiotic pretreatment (AOR, 0.3; 95% CI, 0.1-0.6) was an independent negative predictor of bacteremia in patients who were afebrile.
CONCLUSIONS: A relevant proportion of patients with bacteremic CAP was afebrile. These patients had an increased mortality rate compared with patients with febrile bacteremia or nonbacteremic pneumonia. Therefore, the relevance of fever as an indicator for BC necessity merits reconsideration.
Copyright © 2019 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  bacteremia; community-acquired pneumonia (CAP); fever; predictor

Mesh:

Substances:

Year:  2019        PMID: 31669433     DOI: 10.1016/j.chest.2019.10.006

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  5 in total

1.  Clinical and Microbiological Characteristics of Bacteremic Pneumonia Caused by Klebsiella pneumoniae.

Authors:  I-Ren Chen; Shih-Neng Lin; Xin-Ni Wu; Sheng-Hua Chou; Fu-Der Wang; Yi-Tsung Lin
Journal:  Front Cell Infect Microbiol       Date:  2022-06-23       Impact factor: 6.073

2.  Bloodstream infections in head and neck cancer patients after curative-intent radiotherapy: a population-based study from the Danish Head and Neck Cancer Group database.

Authors:  Kristian Hastoft Jensen; Ivan Vogelius; Claus Ernst Moser; Elo Andersen; Jesper Grau Eriksen; Jørgen Johansen; Mohammad Farhadi; Maria Andersen; Jens Overgaard; Jeppe Friborg
Journal:  Br J Cancer       Date:  2021-05-20       Impact factor: 7.640

3.  Shift in bacterial etiology from the CAPNETZ cohort in patients with community-acquired pneumonia: data over more than a decade.

Authors:  A Essig; D C W Braeken; M Panning; R Hoerster; M Nawrocki; K Dalhoff; N Suttorp; T Welte; M W Pletz; M Witzenrath; G G U Rohde; J Rupp
Journal:  Infection       Date:  2021-03-27       Impact factor: 3.553

Review 4.  [New predictive models of bacteremia in the emergency department: a step forward].

Authors:  A Julián-Jiménez; R Rubio-Díaz; J González Del Castillo; F J Candel
Journal:  Rev Esp Quimioter       Date:  2022-04-13       Impact factor: 2.515

Review 5.  Unmet needs in pneumonia research: a comprehensive approach by the CAPNETZ study group.

Authors:  Mathias W Pletz; Andreas Vestergaard Jensen; Christina Bahrs; Claudia Davenport; Jan Rupp; Martin Witzenrath; Grit Barten-Neiner; Martin Kolditz; Sabine Dettmer; James D Chalmers; Daiana Stolz; Norbert Suttorp; Stefano Aliberti; Wolfgang M Kuebler; Gernot Rohde
Journal:  Respir Res       Date:  2022-09-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.